CL2016000028A1 - Formulación en polvo seco que comprende un anticolinérgico, un corticosteroide y un beta-adrenérgico para administrar por inhalación - Google Patents

Formulación en polvo seco que comprende un anticolinérgico, un corticosteroide y un beta-adrenérgico para administrar por inhalación

Info

Publication number
CL2016000028A1
CL2016000028A1 CL2016000028A CL2016000028A CL2016000028A1 CL 2016000028 A1 CL2016000028 A1 CL 2016000028A1 CL 2016000028 A CL2016000028 A CL 2016000028A CL 2016000028 A CL2016000028 A CL 2016000028A CL 2016000028 A1 CL2016000028 A1 CL 2016000028A1
Authority
CL
Chile
Prior art keywords
inhalation
dry powder
anticholinergic
corticosteroid
adrenergic
Prior art date
Application number
CL2016000028A
Other languages
English (en)
Inventor
Rossella Musa
Irene Pasquali
Azita Askey-Sarvar
Francesca Schiaretti
Original Assignee
Chiesi Farma Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51292914&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2016000028(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiesi Farma Spa filed Critical Chiesi Farma Spa
Publication of CL2016000028A1 publication Critical patent/CL2016000028A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/02—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of powders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Reciprocating Pumps (AREA)

Abstract

FORMULACION EN POLVO SECO PARA USAR EN INHALADOR QUE COMPRENDE: A) PARTICULAS FINAS DE ESTEARATO DE MAGNESIO, B) PARTICULAS GRUESAS DE UN EXCIPIENTE Y C) PARTICULAS MICRONIZADAS DE UN ANTICOLINERGICO, UN CORTICOTEROIDE PARA INHALACION (ICS) Y UN AGONISTA B2 DE ACCION PROLONGADA (LABA); PROCESO PARA PREPARARLA; Y DISPOSITIVO.
CL2016000028A 2013-07-11 2016-01-08 Formulación en polvo seco que comprende un anticolinérgico, un corticosteroide y un beta-adrenérgico para administrar por inhalación CL2016000028A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13176114 2013-07-11
EP13194763 2013-11-28

Publications (1)

Publication Number Publication Date
CL2016000028A1 true CL2016000028A1 (es) 2016-08-05

Family

ID=51292914

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016000028A CL2016000028A1 (es) 2013-07-11 2016-01-08 Formulación en polvo seco que comprende un anticolinérgico, un corticosteroide y un beta-adrenérgico para administrar por inhalación

Country Status (35)

Country Link
US (2) US9402825B2 (es)
EP (3) EP3409270B1 (es)
JP (1) JP6426167B2 (es)
KR (2) KR102275904B1 (es)
CN (1) CN105338960B (es)
AR (1) AR129501A2 (es)
AU (1) AU2014289185B2 (es)
BR (1) BR112015030914B1 (es)
CA (1) CA2917752C (es)
CL (1) CL2016000028A1 (es)
CY (2) CY1120806T1 (es)
DK (3) DK3409270T3 (es)
EA (1) EA029125B1 (es)
ES (3) ES2867552T3 (es)
FI (1) FI3569222T3 (es)
GE (2) GEP20186853B (es)
HR (3) HRP20182008T1 (es)
HU (3) HUE039827T2 (es)
IL (1) IL243507A0 (es)
LT (3) LT3409270T (es)
MX (1) MX2016000290A (es)
MY (1) MY176176A (es)
NZ (1) NZ715797A (es)
PE (2) PE20160372A1 (es)
PH (1) PH12016500043B1 (es)
PL (3) PL3019153T3 (es)
PT (1) PT3019153T (es)
RS (3) RS65951B1 (es)
SA (1) SA516370373B1 (es)
SG (1) SG11201600110RA (es)
SI (3) SI3569222T1 (es)
TN (1) TN2016000007A1 (es)
TW (1) TWI642450B (es)
UA (1) UA116907C2 (es)
WO (1) WO2015004243A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20160853A1 (es) 2009-12-23 2016-09-14 Chiesi Farm Spa Terapia combinada para enfermedad pulmonar obstructiva cronica (epoc)
MX368199B (es) * 2012-01-25 2019-09-24 Chiesi Farm Spa Formulación en polvo seco que comprende un corticoesteroide y un beta-adrenérgico para administración por inhalación.
SI3569222T1 (sl) * 2013-07-11 2024-10-30 Chiesi Farmaceutici S.P.A. Formulacija suhega praška, obsegajoča antiholinergik, kortikosteroid in beta-adrenergik, za dajanje z inhalacijo
GB201321717D0 (en) * 2013-12-09 2014-01-22 Pharmachemie Bv Inhalable Medicaments
US9554992B2 (en) 2014-06-09 2017-01-31 Chiesi Farmaceutici S.P.A. Inhalation particles comprising a combination of an anticholinergic, a corticosteroid and a beta-adrenergic
TR201407010A2 (tr) 2014-06-16 2015-12-21 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi Vilanterol formülasyonları.
JP6600961B2 (ja) * 2015-03-30 2019-11-06 ブラザー工業株式会社 表示制御装置、表示制御方法及び記憶媒体
JP6940416B2 (ja) * 2015-05-01 2021-09-29 ボード オブ リージェンツ, ザ ユニバーシティ オブ テキサス システムBoard Of Regents, The University Of Texas System 多剤脆性マトリックス組成物
KR20180082442A (ko) 2015-11-16 2018-07-18 키에시 파르마슈티시 엣스. 피. 에이. 항콜린제, 코르티코스테로이드 및 베타-아드레날린성 약물을 포함하는 건조 분말 제제의 제조 방법
MA50487B1 (fr) 2015-11-16 2021-09-30 Chiesi Farm Spa Procédé de préparation d'une formulation de poudre sèche contenant un anticholinergique, un corticostéroïde et un bêta-adrénergique
EP3538071B1 (en) 2016-11-10 2022-09-14 Medisca Pharmaceutique Inc. Pharmaceutical compounding methods and systems
KR20220155395A (ko) * 2017-05-11 2022-11-22 키에시 파르마슈티시 엣스. 피. 에이. 항콜린제, 코르티코스테로이드 및 베타-아드레날린성 약물을 포함하는 건조 분말 제제의 제조 방법
KR20220155609A (ko) 2017-05-11 2022-11-23 키에시 파르마슈티시 엣스. 피. 에이. 항콜린제, 코르티코스테로이드 및 베타-아드레날린성 약물을 포함하는 건조 분말 제제의 제조 방법
CN109200034A (zh) * 2017-06-30 2019-01-15 正大天晴药业集团股份有限公司 一种可吸入干粉形式的组合物及其制备方法
WO2019060595A1 (en) 2017-09-20 2019-03-28 Teva Branded Pharmaceutical Products R&D, Inc. INHALABLE DRY POWDER MEDICINAL PRODUCT COMPRISING GLYCOPYRRONIUM
CN114514020A (zh) * 2019-09-24 2022-05-17 奇斯药制品公司 用于吸入用干粉制剂的新型载体颗粒
US12029709B2 (en) * 2022-08-11 2024-07-09 De Motu Cordis Pty Ltd Inhalable epinephrine formulation

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070212422A1 (en) * 1999-11-10 2007-09-13 Manfred Keller Dry powder for inhalation
DK1283036T3 (da) 1998-11-13 2008-03-25 Jagotec Ag Törpulver til inhalation
PE20011227A1 (es) 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
GB0015043D0 (en) 2000-06-21 2000-08-09 Glaxo Group Ltd Medicament dispenser
PT1913939T (pt) * 2000-06-27 2017-07-19 Vectura Ltd Formulações para utilização em dispositivos inalatórios
PT2283817T (pt) * 2000-11-30 2016-08-22 Vectura Ltd Método de fabrico de partículas para utilização numa composição farmacêutica
DE60239639D1 (de) 2002-07-31 2011-05-12 Chiesi Farma Spa Pulverinhalator
JO3102B1 (ar) * 2004-03-17 2017-09-20 Chiesi Framaceutici S P A صيغ صيدلانية لوسائل استنشاق بها مسحوق جاف تشتمل على مكون فعال بقوة منخفضة الجرعة
GB0425758D0 (en) * 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
GB0613161D0 (en) 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
EP1944018A1 (en) * 2007-01-10 2008-07-16 CHIESI FARMACEUTICI S.p.A. Micronised particles of low-dosage strength active agents for powder formulations for inhalation
BR112012015334A2 (pt) 2009-12-23 2016-03-15 Chiesi Farma Spa terapia combinada para doença pulmonar obstrutiva crônica
PE20160853A1 (es) 2009-12-23 2016-09-14 Chiesi Farm Spa Terapia combinada para enfermedad pulmonar obstructiva cronica (epoc)
TR201000681A2 (tr) 2010-01-29 2011-08-22 B�Lg�� Mahmut İnhalasyon yoluyla alınan kuru toz formülasyonları.
RU2585101C2 (ru) * 2010-04-01 2016-05-27 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Способ приготовления частиц носителя для сухих порошков для ингаляции
HUE038555T2 (hu) * 2010-04-21 2018-10-29 Chiesi Farm Spa Eljárás csökkentett elektrosztatikus töltéssel rendelkezõ részecskék elõállítására
UA107499C2 (uk) * 2010-06-22 2015-01-12 Chiesi Farm Spa Склад сухого порошку, який містить антимускариновий засіб
MX368199B (es) 2012-01-25 2019-09-24 Chiesi Farm Spa Formulación en polvo seco que comprende un corticoesteroide y un beta-adrenérgico para administración por inhalación.
US9393202B2 (en) 2013-04-26 2016-07-19 Chiesi Farmaceutici S.P.A Particle size reduction of an antimuscarinic compound
SI3569222T1 (sl) * 2013-07-11 2024-10-30 Chiesi Farmaceutici S.P.A. Formulacija suhega praška, obsegajoča antiholinergik, kortikosteroid in beta-adrenergik, za dajanje z inhalacijo

Also Published As

Publication number Publication date
AR129501A2 (es) 2024-09-04
GEP20186853B (en) 2018-05-25
ES2867552T3 (es) 2021-10-20
RS61652B1 (sr) 2021-04-29
HRP20182008T1 (hr) 2019-01-25
ES2986128T3 (es) 2024-11-08
RS57799B1 (sr) 2018-12-31
JP6426167B2 (ja) 2018-11-21
PL3409270T3 (pl) 2021-08-09
EP3019153B1 (en) 2018-09-05
HRP20210704T1 (hr) 2021-06-11
CN105338960A (zh) 2016-02-17
CA2917752C (en) 2022-05-03
SI3409270T1 (sl) 2021-07-30
DK3019153T3 (en) 2018-11-19
HRP20241300T1 (hr) 2024-12-06
MY176176A (en) 2020-07-24
CA2917752A1 (en) 2015-01-15
MX2016000290A (es) 2016-04-13
PL3019153T3 (pl) 2019-02-28
TW201536352A (zh) 2015-10-01
IL243507A0 (en) 2016-02-29
US9808422B2 (en) 2017-11-07
CY1123937T1 (el) 2022-05-27
CY1120806T1 (el) 2019-12-11
KR20210075217A (ko) 2021-06-22
SI3569222T1 (sl) 2024-10-30
FI3569222T3 (fi) 2024-09-24
EA029125B1 (ru) 2018-02-28
KR102275904B1 (ko) 2021-07-13
PL3569222T3 (pl) 2024-10-28
AU2014289185B2 (en) 2019-05-23
CN105338960B (zh) 2019-06-04
SA516370373B1 (ar) 2017-10-11
GEAP201814032A (en) 2018-01-25
JP2016523950A (ja) 2016-08-12
SI3019153T1 (sl) 2018-12-31
BR112015030914B1 (pt) 2023-04-04
LT3019153T (lt) 2018-11-26
US20160263027A1 (en) 2016-09-15
EP3409270A1 (en) 2018-12-05
AU2014289185A1 (en) 2016-02-04
TWI642450B (zh) 2018-12-01
LT3569222T (lt) 2024-09-25
HUE068270T2 (hu) 2024-12-28
EP3019153A1 (en) 2016-05-18
HUE053957T2 (hu) 2021-08-30
ES2699986T3 (es) 2019-02-13
UA116907C2 (uk) 2018-05-25
WO2015004243A1 (en) 2015-01-15
BR112015030914A2 (es) 2017-07-25
PH12016500043B1 (en) 2018-11-23
HK1218712A1 (zh) 2017-03-10
PE20160372A1 (es) 2016-05-19
EA201690006A1 (ru) 2016-07-29
EP3569222A1 (en) 2019-11-20
EP3409270B1 (en) 2021-02-24
SG11201600110RA (en) 2016-02-26
EP3569222B1 (en) 2024-06-26
RS65951B1 (sr) 2024-10-31
DK3569222T3 (da) 2024-08-19
PH12016500043A1 (en) 2016-03-28
TN2016000007A1 (en) 2017-07-05
LT3409270T (lt) 2021-07-26
HUE039827T2 (hu) 2019-02-28
DK3409270T3 (da) 2021-04-26
US20150017248A1 (en) 2015-01-15
PT3019153T (pt) 2018-12-04
KR20160029797A (ko) 2016-03-15
PE20212110A1 (es) 2021-11-04
NZ715797A (en) 2020-06-26
US9402825B2 (en) 2016-08-02

Similar Documents

Publication Publication Date Title
CO2017004649A2 (es) Esteroides neuroactivos para trastornos del snc
AR098640A1 (es) Inhalador de polvo seco
MX2015013247A (es) Formulacion de acetato de abiraterona.
MX2021008113A (es) Composiciones farmaceuticas que comprenden un antagonista de il-4r para usarse en el tratamiento del asma.
UY34984A (es) Métodos para tratar o prevenir asma administrando un antagonista de il-4r.
MX2016003216A (es) Metodos y composiciones farmaceuticas para el tratamiento de la infeccion por el virus de la hepatitis b.
CL2015002632A1 (es) Aglomerados respirables de partículas de vehículo porosas y fármaco micronizado
UY35210A (es) Inhibidores de autotaxina
GEP20186853B (en) Dry powder formulation comprising anticholinergic, corticosteroid and beta-adrenergic for administration by inhalation
BR112018070199A2 (pt) composição farmacêutica de hormônio esteroide
GT201400182A (es) Formulaciones farmacéuticas novedosas
CL2016000735A1 (es) Inhalador de polvo seco que comprende una composición farmacéutica inhalable que comprende propionato de fluticasona, xinafoato de salmeterol y un vehículo de lactosa; uso para tratar asma o epoc.
MX2016000271A (es) Metodos para el tratamiento de la esofagitis eosinofilica mediante la administracion de un inhibidor de il-4r.
DOP2015000100A (es) Inhibidores de la tirosina-quinasa de bruton
DOP2015000284A (es) Composiciones, métodos y sistemas para el suministro por vía respiratoria de tres o más agentes activos
HUE040525T2 (hu) Kortikoszteroidot és béta-adrenerg szert tartalmazó száraz por készítmény inhalálással történõ beadásra
AR093382A1 (es) Dispositivo de administracion de farmacos para el tratamiento de pacientes con enfermedades respiratorias
MX2016004530A (es) Rapamicina para el tratamiento de linfangioleiomiomatosis.
BR112015027017A2 (pt) composições farmacêuticas inaláveis e dispositivos inaladores que contêm as mesmas
AR099364A1 (es) Inhalador de medicamentos
CL2016000677A1 (es) Compuestos derivados de etinilo, moduladores alostericos positivos del receptor mglur4; composicion farmaceutica que los comprende; y su uso en enfermedades del snc, cancer y diabetes tipo 2.
MX2015009891A (es) Composiciones farmaceuticas que comprenden particulas cristalinas de multicomponentes adecuadas para usar en terapia de inhalacion.
CL2016001436A1 (es) Formas de dosificación farmacéuticas
UY35526A (es) Derivados de espiroindolina y composiciones farma céuticas de los mismos
MX2019001701A (es) Composicion farmaceutica de dosis fija que comprende mometasona y azelastina.